ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

  • Abstract Number: L09 • ACR Convergence 2024

    Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis

    Hermine Brunner1, Caifeng Li2, Kogie Chinniah3, Yosef Uziel4, Olga Synoverska5, Sujata Sawhney6, Inmaculada Calvo Penades7, Ingrid Clara Louw8, Meiping Lu9, Pooja Nikunj Patel10, Pamela F. Weiss11, Cheng Chang12, Ivana Vranic13, Shixue Liu14, Annette Diehl15, Jose L. Rivas16, Carol A. Connell17, Gary G. Koch18, Alberto Martini19, Daniel J. Lovell1, Nicolino Ruperto20 and the PRINTO and PRCSG investigators, 1Cincinnati Children’s Hospital Medical Center, and University of Cincinnati, Cincinnati, OH, 2Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Bejing, China, 3Department of Paediatrics and Child Health, University of Kwa-Zulu, and Enhancing Care Foundation, Durban, South Africa, 4Pedriatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center and Israel Tel Aviv University School of Medicine, Kfar Saba, Israel, 5Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine, 6Sir Ganga Ram Hospital, New Delhi, India, 7Hospital Universitario y Politécnico La Fe, Valencia, Spain, 8Panorama Medical Centre, Cape Town, South Africa, 9Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, 10Ann & Robert H. Lurie Children’s Hospital of Chicago; Northwestern University School of Medicine, Chicago, IL, 11Division of Rheumatology, Children's Hospital of Philadelphia, and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 12Pfizer Inc, New York, NY, 13Pfizer Ltd, Tadworth, United Kingdom, 14Pfizer Inc, Shanghai, China, 15Pfizer Inc, Collegeville, PA, 16Pfizer SLU, Madrid, Spain, 17Pfizer Inc, Groton, CT, 18University of North Carolina at Chapel Hill, Chapel Hill, NC, 19University of Genoa, Genoa, Italy, 20Università Milano Bicocca, Milano, and IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy

    Background/Purpose: Tofacitinib (TOF) has been shown to be efficacious in the treatment of polyarticular course JIA, including systemic JIA (sJIA) without active systemic features. Here…
  • Abstract Number: 0252 • ACR Convergence 2024

    Prospective Study of Severe Infectious Events and Immune Reconstitution After Rituximab in Autoimmune Diseases

    Aurélien Chepy1, Michaël Genin2, Louis Terriou3, Cécile Chenivesse4, Delphine Staumont-Sallé5, Hélène Zéphir6, Peggy philippe7, Guillaume Lefevre8, Sarah Stabler9, Eric HACHULLA3, David Launay10 and Vincent Sobanski3, 1Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France., Lille, Nord-Pas-de-Calais, France, 2Univ. Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, F-59000, France., Lille, France, 3CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille, France, 4Centre de Référence Constitutif des Maladies Pulmonaires Rares, CHU Lille, Service de Pneumologie et Immuno-Allergologie, Lille 59000, France., Lille, France, 5Service de dermatologie CHU Lille Université de Lille Lille France., Lille, France, 6Department of Neurology, CRC-SEP, CHU of Lille, Lille, France., Lille, France, 7Rheumatology Department, Lille University Hospital, Lille, France., Lille, France, 8CHU Lille, Institut d’Immunologie, Lille, France., Lille, France, 9CHU Lille, Service Universitaire de Maladies Infectieuses, F-59000 Lille, France; Univ. Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Lille, France, 10CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille Cedex, France

    Background/Purpose: Rituximab (RTX) administration in autoimmune diseases (AID) is associated with severe infectious events (SIE). Frequency of SIE and immune reconstitution (B cells, T cells,…
  • Abstract Number: 0506 • ACR Convergence 2024

    24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: The 2024 Interim Report

    Takao Fujii1, Nami Okamoto2, Asami Abe3, Michiaki Takagi4, Nobunori Takahashi5, Atsuo Nakajima6, Ayako Nakajima7, Shingo Nakayamada8, Keiichiro Nishida9, Takeshi Kawaberi10, Naomi Sunaga10, Yuki Tsujita11, Sumi Chonan12, Masataka Kuwana13 and Yoshiya Tanaka14, 1Wakayama Medical University, Wakayama, Japan, 2Osaka Rosai Hospital, Sakai-city, Osaka, Japan, 3Niigata Rheumatic Center, Shibata, Japan, 4Yamagata University Faculty of Medicine, Yamagata, Japan, 5Nagoya University Graduate School of Medicine, Nagoya, Japan, 6Ueno Dialysis Clinic, Tokyo, Japan, 7Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, 8The First Department of Internal Medicine, University of Occupational and Environmental Health Japan,, Kitakyushu, Japan, 9Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 10Abbvie GK, Minato-Ku, Tokyo, Japan, 11AbbVie, Minato City Tokyo, Japan, 12Abbvie GK, Tokyo, Japan, 13Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, 14Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan

    Background/Purpose: Upadacitinib (UPA) was approved in 2020 in Japan for "the treatment of Rheumatoid arthritis (RA) with inadequate response to conventional therapy (including inhibition of…
  • Abstract Number: 0758 • ACR Convergence 2024

    Difficult to Treat Takayasu Arteritis: Comparative Efficacy of Colchicine and Tofacitinib

    Ravi Kumar1, Prabhu Vasanth2, Ramya Janardhana3, Arvind Ganapati4, Abhishek Patil5, Avinash Jain6, Benzeeta Pinto7, Ramesh Jois8, Shivraj Padiyar9, John Mathew9, Vineeta Shobha3, George Joseph2 and Ruchika goel9, 1Christian Medical college , Vellore , India, Bangalore, India, 2Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, 3St. John’s Medical College, Bengaluru , India, Bangalore, India, 4Kasturba Medical College, Rheumatology Division, Manipal , India, Vellore, Tamil Nadu, India, 5Manipal Hospital, Rheumatology, Bengaluru, India, Bengaluru, India, 6SMS Medical College and Hospital, Jaipur ,India, JAIPUR, India, 7St. John’s Medical College, Bengaluru , India, Bengaluru, India, 8Manipal Hospital ,Rheumatology, Millers Road, Bengaluru, India, Bengaluru, India, 9Christian Medical college , Vellore , India, Vellore, India

    Background/Purpose: Biologic DMARDs (bDMARDs) are mainstay in management of patients with difficult to treat Takayasu Arteritis (D2TTAK). The cost of long-term biologics is prohibitory in…
  • Abstract Number: 1362 • ACR Convergence 2024

    Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting

    Peter C. Taylor1, Aditi Kadakia2, Jack Milligan3, Sander Strengholt2, Oliver Howell3, Pankaj Patel2, Sophie Barlow3 and Roberto Caporali4, 1University of Oxford, Oxford, United Kingdom, 2AbbVie Inc., North Chicago, IL, 3Adelphi Real World, Bollington, United Kingdom, 4Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy

    Background/Purpose: Network meta-analyses of phase 3 clinical trial data involving JAK inhibitor (JAKi)-treated patients with RA and an inadequate response to conventional synthetic DMARDs showed…
  • Abstract Number: 1461 • ACR Convergence 2024

    Uveitis in Axial Spondyloarthritis: Study of 309 Patients in a Single University Center

    Lourdes Martin-Sierra1, Lara Sanchez Bilbao2, Javier Rueda Gotor3, Vanesa Calvo-Rio4, Angela Egea-Fuentes5, Alba Herrero-Morant6, Inigo Gonzalez-Mazon7, Jose Ramon Muñoz-Rodriguez8 and Ricardo Blanco-Alonso9, 1Hospital General Universitario de Ciudad Real, Ciudad Real, Castilla-La Mancha, Spain, 2Rheumatology and Ophthalmology. Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 3Hospital Sierrallana, Torrelavega, Cantabria, Spain, 4Valdecilla Hospital, Santander, Cantabria, Spain, 5Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, 6Hospital Universitario Marqués de Valdecilla, Ontinyent, Cantabria, Spain, 7H. U. Marques de Valdecilla, Santander, Cantabria, Spain, 8Hospital General Universitario de Ciudad Real, Unidad de Investigación Traslacional de la Gerencia de Atención Integrada de Ciudad Real, Ciudad Real, Castilla-La Mancha, Spain, 9Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Uveitis is a frequent extraarticular manifestation of axial Spondyloarthritis (axSpA), specifically anterior uveitis. Effects of biological therapy on uveitis associated to axSpA are poorly…
  • Abstract Number: 1758 • ACR Convergence 2024

    Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis over 2 Years of Bimekizumab Treatment: Results from a Phase 3 Open-Label Extension Study

    Xenofon Baraliakos1, Sofia Ramiro2, Walter Maksymowych3, Mikkel Ostergaard4, Ute Massow5, Thomas Vaux6, Chetan Prajapati6, Alexander Marten5, Natasha de Peyrecave7 and Denis Poddubnyy8, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 2Leiden University Medical Center, Bunde, Netherlands, 3University of Alberta, Edmonton, AB, Canada, 4Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, 5UCB Pharma, Monheim am Rhein, Germany, 6UCB Pharma, Slough, United Kingdom, 7UCB Pharma, Brussels, Belgium, 8Charite-Universitatsmedizin Berlin, Berlin, Germany

    Background/Purpose: The effect of bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, on structural radiographic progression in the…
  • Abstract Number: 2265 • ACR Convergence 2024

    Patient’s Global Assessment of Disease Activity Is the Most Relevant Factor for Near-Miss of Boolean 2.0 Remission in Patients with Rheumatoid Arthritis: Post Hoc Analysis from the Observational UPwArds Study

    Torsten Witte1, Uta Kiltz2, Florian Haas3, Elke Riechers4, Ulrich Prothmann5, Daniela Adolf6, Alexander Rössler7, Kirsten Famulla8, Konrad Götz7 and Klaus Krüger9, 1Dept of Immunology and Rheumatology, Hannover, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 3Internistisch-Rheumatologische Facharztpraxis, Rheumatology, Tübingen, Germany, 4Hannover Medical School, Department for Rheumatology and Immunology, Herne, Germany, 5Knappschaftsklinikum Saar GmbH, Püttlingen, Germany, 6StatConsult GmbH, Statistics, Magdeburg, Germany, 7AbbVie Deutschland GmbH & Co. KG, Immunology, Wiesbaden, Germany, 8AbbVie Deutschland GmbH & Co. KG, Immunology, North Chicago, 9Rheumatologisches Praxiszentrum, Munich, Germany, München, Germany

    Background/Purpose: Patient’s Global Assessment of disease activity (PtGA) was found to be the most relevant limiting factor for achieving Boolean 1.0 remission in patients with…
  • Abstract Number: 0253 • ACR Convergence 2024

    Outcomes of Respiratory Syncytial Virus Infection in Patients with Systemic Autoimmune Rheumatic Diseases

    Justine Enns1, Shruthi Srivatsan1, Bohang Jiang1, Miao Lin1, Emily Kowalski2, Naomi Patel1, Xiaosong Wang3, Zachary Williams1, Grace Qian3, Jennifer Hanberg1, Colebrook Johnson1, Madison Negron1, Katarina Bade2, Alene Saavedra2, Kevin Mueller2, Kathleen Vanni3, Jeffrey Sparks4 and Zachary Wallace5, 1Massachusetts General Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women’s Hospital, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 5Massachusetts General Hospital, Newton, MA

    Background/Purpose: Respiratory Syncytial Virus (RSV) can cause a severe respiratory illness, especially in older adults and those with significant comorbidities. In June 2023 the US…
  • Abstract Number: 0516 • ACR Convergence 2024

    Management of Elederly Patients with Rheumatoid Arthritis Treated with Tocilizumab : Comparison of Patients over and Under 75 Years Old

    Bruno Fautrel1, Alain SARAUX2, Isabelle Idier3, Henri Bonnabau4, Geoffray Bizouard5 and BERNARD COMBE6, 1INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, 2CHU Brest, Brest, France, 3Chugai Pharma france, Puteaux, Ile-de-France, France, 4IQVIA France, Bordeaux, France, 5IQVIA France, La Defense, Ile-de-France, France, 6Montpellier University, LA GRANDE MOTTE, Languedoc-Roussillon, France

    Background/Purpose: Few real-life long-term data are available in RA patients initiating tocilizumab (TCZ) depending on age. The objective of this study was to compare the…
  • Abstract Number: 0856 • ACR Convergence 2024

    Comparative Effectiveness of Disease Modifying Antirheumatic Drugs for Cardiac Sarcoidosis

    Michael Putman1, Lisbeth Brooks2, William Kivlin2, Divyanshu Mohananey2 and Viktoriya Sabchyshyn2, 1The Medical College of Wisconsin, Milwaukee, WI, 2Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: No studies to date have evaluated the comparative efficacy of disease modifying antirheumatic drugs (DMARDs) for cardiac sarcoidosis. Methods: We performed a retrospective cohort…
  • Abstract Number: 1367 • ACR Convergence 2024

    Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY

    James Galloway1, Jérôme Avouac2, Gerd Burmester3, Roberto Caporali4, Thomas P.A. Debray5, Katrien Van Beneden6, Neil Betteridge7, Susana Romero Yuste8, Monia Zignani5, Patrick Verschueren9 and Karen Bevers10, 1Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 2Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 3Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 4Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, 5Alfasigma S.p.A., Bologna, Italy, 6Medical Affairs, Galapagos NV, Mechelen, Belgium, 7Neil Betteridge Associates, Lonodn, United Kingdom, 8Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, 9Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, 10Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients with RA. This interim analysis evaluated effectiveness and…
  • Abstract Number: 1467 • ACR Convergence 2024

    Time to First Clinically Meaningful Efficacy Responses in Musculoskeletal and Patient Reported Outcomes in Patients with Active Psoriatic Arthritis Treated with Risankizumab: A Post Hoc Analysis of the Phase 3 KEEPsAKE 1 and KEEPsAKE 2 Trials

    William Tillett1, Simona Rednic2, Kristi Mizelle3, Christopher Ritchlin4, Saakshi Khattri5, Linyu Shi6, Brenton Bialik6, Thomas Iyile7 and Arthur Kavanaugh8, 1Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, 2Department of Rheumatology, "Iuliu Hațieganu" University of Medicine and Pharmacy and County Emergency Hospital, Cluj-Napoca, Romania, 3Tidewater Physicians Multispecialty Group (TPMG) Rheumatology, Newport News, VA, 4Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 5Mount Sinai Medical Center, New York, NY, 6AbbVie Inc., North Chicago, IL, 7AbbVie Inc., hyattsville, MD, 8University of California San Diego, La Jolla, CA

    Background/Purpose: The phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized double-blind clinical trials demonstrate that risankizumab (RZB) provides a high level of durable improvement in…
  • Abstract Number: 1786 • ACR Convergence 2024

    Select Immune Cell Dysregulation Identifies Clinically Quiescent Patients at Risk of Flare Who Stop Mycophenolate Mofetil While Continuing Hydroxychloroquine

    Christian Wright1, Rufei Lu2, Catriona Wagner3, Carla Guthridge4, Susan Macwana1, Eliza Chakravarty4, Tammy Utset5, Diane Kamen6, Gabriel Nicolas Contreras Martin7, William McCune8, Cynthia Aranow9, Kenneth Kalunian10, Elena Massarotti11, Megan Clowse12, Brad Rovin13, S. Sam Lim14, Vikas Majithia15, Richard Looney16, Maria Dall'Era17, Doruk Erkan18, Amit Saxena19, Nancy Olsen20, Kichul Ko21, Ellen Goldmuntz22, William Barry23, Ashley Pinckney24, ALE06 Clinical Study Team4, Judith James4 and Joel Guthridge4, 1Oklahoma Medical Research Foundation, Oklahoma City, 2University of California San Francisco, San Bruno, CA, 3Oklahoma Medical Research Foundation, Santa Cruz, CA, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5University of Chicago, Chicago, IL, 6Medical University of South Carolina, Charleston, SC, 7University of Miami, Key Biscayne, FL, 8U Michigan, Ann Arbor, MI, 9Feinstein Institutes for Medical Research, New York, NY, 10University of California San Diego, La Jolla, CA, 11Brigham and Women's Hospital, Boston, MA, 12Duke University, Chapel Hill, NC, 13The Ohio State University, Columbus, OH, 14Emory University, Atlanta, GA, 15Mayo Clinic Florida, Jacksonville, FL, 16University of Rochester, Rochester, NY, 17UCSF, Corte Madera, CA, 18Hospital for Special Surgery, New York, NY, 19NYU School of Medicine, New York, NY, 20Penn State University/Milton S Hershey, Hershey, PA, 21The University of Chicago, Chicago, IL, 22NIAID/ NIH, Washington, DC, 23Rho, Inc, Durham, NC, 24Rho, St Louis Park, NC

    Background/Purpose: Mycophenolate mofetil (MMF) is commonly used to treat major SLE manifestations; however, it is associated with significant toxicities. Thus, MMF withdrawal is desirable in…
  • Abstract Number: 2266 • ACR Convergence 2024

    Immunosuppressive Medications and Common Infections in Patients with Rheumatoid Arthritis

    Michael George1, Kelly Gavigan2, Shilpa Venkatachalam3, David Curtis2, Laura Stradford4, William Benjamin Nowell5, Fenglong Xie6, Joshua Baker1 and Jeffrey Curtis7, 1University of Pennsylvania, Philadelphia, PA, 2Global Healthy Living Foundation, Upper Nyack, NY, 3Global Healthy Living Foundation, New York, NY, 4Global Healthy Living Foundation, Nyack, NY, 5Regeneron, New York, NY, 6University of Alabama at Birmingham, Birmingham, AL, 7University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Patients with RA are at increased risk of serious infection, but less is known about common, non-serious infections. Our prospective study aimed to assess…
  • 1
  • 2
  • 3
  • …
  • 40
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology